New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations (English)
- New search for: Bigagli, Elisabetta
- New search for: Luceri, Cristina
- New search for: De Angioletti, Maria
- New search for: Chegaev, Konstantin
- New search for: D’Ambrosio, Mario
- New search for: Riganti, Chiara
- New search for: Gazzano, Elena
- New search for: Saponara, Simona
- New search for: Longini, Mariangela
- New search for: Luceri, Francesca
- New search for: Cinci, Lorenzo
- Further information on Cinci, Lorenzo:
- https://orcid.org/0000-0002-1799-4828
- New search for: Bigagli, Elisabetta
- New search for: Luceri, Cristina
- New search for: De Angioletti, Maria
- New search for: Chegaev, Konstantin
- New search for: D’Ambrosio, Mario
- New search for: Riganti, Chiara
- New search for: Gazzano, Elena
- New search for: Saponara, Simona
- New search for: Longini, Mariangela
- New search for: Luceri, Francesca
- New search for: Cinci, Lorenzo
- Further information on Cinci, Lorenzo:
- https://orcid.org/0000-0002-1799-4828
In:
Investigational New Drugs
;
36
, 6
; 985-998
;
2018
-
ISSN:
- Article (Journal) / Electronic Resource
-
Title:New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations
-
Contributors:Bigagli, Elisabetta ( author ) / Luceri, Cristina ( author ) / De Angioletti, Maria ( author ) / Chegaev, Konstantin ( author ) / D’Ambrosio, Mario ( author ) / Riganti, Chiara ( author ) / Gazzano, Elena ( author ) / Saponara, Simona ( author ) / Longini, Mariangela ( author ) / Luceri, Francesca ( author )
-
Published in:Investigational New Drugs ; 36, 6 ; 985-998
-
Publisher:
- New search for: Springer US
- New search for: Springer Science + Business Media B.V
-
Place of publication:Dordrecht [u.a.]
-
Publication date:2018
-
ISSN:
-
ZDBID:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
- New search for: 44.40 / 44.40$jPharmazie$jPharmazeutika
- Further information on Basic classification
-
Keywords:
-
Classification:
BKL: 44.40 Pharmazie, Pharmazeutika / 44.40$jPharmazie$jPharmazeutika -
Source:
Table of contents – Volume 36, Issue 6
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 961
-
Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cellsLiu, Songlin / Tang, Yunhong / Yuan, Xianrui / Yuan, Dun / Liu, Junyu / Li, Buyan / Li, Yifeng et al. | 2018
- 970
-
The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivatives in human gastric cancer cellsPawłowska, Natalia / Gornowicz, Agnieszka / Bielawska, Anna / Surażyński, Arkadiusz / Szymanowska, Anna / Czarnomysy, Robert / Bielawski, Krzysztof et al. | 2018
- 985
-
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluationsBigagli, Elisabetta / Luceri, Cristina / De Angioletti, Maria / Chegaev, Konstantin / D’Ambrosio, Mario / Riganti, Chiara / Gazzano, Elena / Saponara, Simona / Longini, Mariangela / Luceri, Francesca et al. | 2018
- 999
-
Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutationOsoegawa, Atsushi / Hashimoto, Takafumi / Takumi, Yohei / Abe, Miyuki / Yamada, Tomonori / Kobayashi, Ryoji / Miyawaki, Michiyo / Takeuchi, Hideya / Okamoto, Tatsuro / Sugio, Kenji et al. | 2018
- 1006
-
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dosede Vries Schultink, Aurelia H. M. / Doornbos, Robert P. / Bakker, Alexander B. H. / Bol, Kees / Throsby, Mark / Geuijen, Cecile / Maussang, David / Schellens, Jan H. M. / Beijnen, Jos H. / Huitema, Alwin D. R. et al. | 2018
- 1016
-
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsAghajanian, Carol / Bell-McGuinn, Katherine M. / Burris, Howard A. / Siu, Lillian L. / Stayner, Lee-Ann / Wheler, Jennifer J. / Hong, David S. / Kurkjian, Carla / Pant, Shubham / Santiago-Walker, Ademi et al. | 2018
- 1026
-
A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumoursAung, Kyaw L. / El-Khoueiry, Anthony B. / Gelmon, Karen / Tran, Ben / Bajaj, Gaurav / He, Bing / Chen, Tian / Zhu, Lili / Poojary, Sharath / Basak, Shashwati et al. | 2018
- 1037
-
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancerFinn, R. S. / Ahn, D. H. / Javle, M. M. / Tan, B. R. / Weekes, C. D. / Bendell, J. C. / Patnaik, A. / Khan, G. N. / Laheru, D. / Chavira, R. et al. | 2018
- 1044
-
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumorsHiret, Sandrine / Isambert, Nicolas / Gomez-Roca, Carlos / Bennouna, Jaafar / Sassi, Mouna / de Mont-Serrat, Hélène / Fan, Jean / Schnell, David / Delord, Jean-Pierre et al. | 2018
- 1060
-
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsCarducci, Michael / Shaheen, Montaser / Markman, Ben / Hurvitz, Sara / Mahadevan, Daruka / Kotasek, Dusan / Goodman, Oscar B. / Rasmussen, Erik / Chow, Vincent / Juan, Gloria et al. | 2018
- 1072
-
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsTak, Won Young / Ryoo, Baek-Yeol / Lim, Ho Yeong / Kim, Do-Young / Okusaka, Takuji / Ikeda, Masafumi / Hidaka, Hisashi / Yeon, Jong-Eun / Mizukoshi, Eishiro / Morimoto, Manabu et al. | 2018
- 1085
-
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II studyBarata, Pedro C. / Cooney, Matthew / Mendiratta, Prateek / Tyler, Allison / Dreicer, Robert / Garcia, Jorge A. et al. | 2018
- 1093
-
Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 casesTakahara, Naminatsu / Nakai, Yousuke / Isayama, Hiroyuki / Sasaki, Takashi / Saito, Kei / Oyama, Hiroki / Kanai, Sachiko / Suzuki, Tatsunori / Sato, Tatsuya / Hakuta, Ryunosuke et al. | 2018
- 1103
-
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-βYam, Clinton / Murthy, Rashmi K. / Rauch, Gaiane M. / Murray, James L. / Walters, Ronald S. / Valero, Vicente / Brewster, Abenaa M. / Bast, Robert C. / Booser, Daniel J. / Giordano, Sharon H. et al. | 2018
- 1110
-
Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisoneRoviello, Giandomenico / Petrioli, Roberto / Bonetta, Alberto / Conca, Raffaele / Rodriquenz, Maria Grazia / Aieta, Michele et al. | 2018
- 1116
-
Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcomaWang, Chongchong / Jing, Juehua / Cheng, Li et al. | 2018
- 1133
-
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancerSobhani, Navid / Generali, Daniele / D’Angelo, Alberto / Aieta, Michele / Roviello, Giandomenico et al. | 2018
- 1138
-
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reactionKunimasa, Kei / Isei, Taiki / Nakamura, Harumi / Kimura, Madoka / Inoue, Takako / Tamiya, Motohiro / Nishino, Kazumi / Kumagai, Toru / Nakatsuka, Shin-ichi / Endo, Hiroko et al. | 2018
- 1143
-
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaintsStump, Sarah E. / Whang, Young E. / Crona, Daniel J. et al. | 2018
- 1147
-
Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitorsGuo, Shewei / Zhen, Yingwei / Guo, Mengguo / Zhang, Longzhou / Zhou, Guosheng et al. | 2018
- 1158
-
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerGoff, Laura W. / Azad, Nilofer S. / Stein, Stacey / Whisenant, Jennifer G. / Koyama, Tatsuki / Vaishampayan, Ulka / Hochster, Howard / Connolly, Roisin / Weise, Amy / LoRusso, Patricia M. et al. | 2018